VIVEbiotech, a leading lentiviral vector Contract Development and Manufacturing Organization (CDMO), underscored its industry leadership in the development and manufacturing of in vivo cell and gene therapy (CGT) vectors with the addition of its 15th in vivo lentiviral vector-based therapeutic program using its well-established platform. These programs, several of which have already received regulatory clearance […]
Post Type Archives: News
Lonza Grants Exclusive, Target-Specific License to Antharis Therapeutics to Advance Next-Generation Dual Payload ADCs for Gastrointestinal Cancers
Lonza and Antharis Therapeutics, Inc., a biopharmaceutical company developing next-generation antibody-based therapeutics for oncology, announced an exclusive, target-specific licensing agreement to develop novel dual-payload ADCs targeting gastrointestinal (GI) cancers. Antharis Therapeutics utilizes cutting-edge proprietary antibody engineering and target biology expertise to develop next-generation therapeutic monoclonal antibodies (mAbs), bispecifics and ADCs, designed to address unmet medical needs in oncology. Through this agreement, Antharis will integrate its proprietary antibody engineering and target biology expertise with Lonza’s clinically validated, […]
ZoBio launches comprehensive DEL hit discovery service for challenging targets
ZoBio, a boutique problem-solving Contract Research Organization (CRO) specializing in early gene-to-lead discovery, today announced the launch of its comprehensive DNA-Encoded Library (DEL) hit discovery service, designed to help biotech and pharmaceutical companies generate validated, progressible hits against novel and challenging drug targets. The new integrated offering combines structure-grade protein production, quantitative biophysics, DEL screening, […]
CPHI launches new Sustainability Summit as pharma faces growing pressure to deliver sustainability goals
CPHI has announced the launch of the CPHI Sustainability Summit, a new two-day event dedicated to advancing sustainability across the pharmaceutical value chain. Taking place at Fiera Milano, Italy, on 5-6 October 2026, alongside CPHI Milan, the summit will bring together more than 300 sustainability leaders, pharmaceutical executives and supply chain stakeholders to discuss practical action on one of […]
GELITA Unveils Next-Generation Excipient Innovations at BIO International 2026 in San Diego
GELITA, a global leader in collagen protein solutions, will showcase its latest advancements in excipient technology at BIO International 2026 in San Diego (Booth 3335-DF). Renowned for its expertise in gelatin and collagen peptides, GELITA continues to set new standards for safety, performance, and sustainability in the pharmaceutical and medical device sectors. GELITA’s Endotoxin Controlled […]
Johnson & Johnson Expands Oncology Pipeline with $1 Billion Firefly Bio Acquisition
Johnson & Johnson announced a definitive agreement to acquire Firefly Bio, a biotechnology advancing the Firelink degrader antibody conjugate (DAC) platform, on June 8th, 2026. The $1 billion, all-cash deal is expected to close later this year, according to a press release issued by Johnson & Johnson. Firefly’s current DAC platform, Firelink, is designed to […]
Axplora consolidates UDCA manufacturing at Vizag site to strengthen integrated global supply and support future growth
Axplora, a global leader in the manufacturing of small molecule APIs and ADCs for the pharmaceutical industry, today announced the strategic consolidation of ursodeoxycholic acid (UDCA) manufacturing at its Vizag, India site, part of the PharmaZell business unit. Production will transition fully from the company’s Gropello Cairoli, Italy site — the renowned manufacturing site within […]
Symeres expands spray drying capabilities to accelerate complex small molecule development
Symeres, a leading contract research, development, and manufacturing organisation (CRDMO), has expanded its spray drying capabilities at its Cranbury, New Jersey, Chemistry, Manufacturing and Controls (CMC) development site to support formulation development for poorly soluble and development-challenged small molecule drug candidates. The expanded capability is designed to support bioavailability enhancement strategies, including amorphous solid dispersions […]
AmMax Bio Licenses Antibody-Drug Conjugate Technology for Hematological Cancers from Lonza
AmMax Bio, Inc., a private clinical-stage biopharmaceutical company developing an innovative portfolio of antibody-drug conjugates in oncology, and Lonza, the world’s leading contract development and manufacturing organization (CDMO), today announced a non-exclusive licensing agreement. AmMax has engineered AMB-104 that combines Lonza’s technologies with its clinically-validated monoclonal antibody to deliver a tumor-targeted cytotoxic payload for treating […]
Lonza Appoints Hans Trees as Global Head of Communications
Lonza announced the appointment of Hans Trees as Global Head of Communications, Senior Vice President and member of the Extended Executive Committee. Hans will join Lonza on 1 September 2026 and succeed David Carter, who has led Lonza’s Communications function since 2019. Hans is a seasoned communications executive with broad experience across communications, strategy and […]